研究者業績

近藤 征史

Masashi Kondo

基本情報

所属
藤田医科大学 医学部 医学科 臨床教授
学位
MD(名古屋大学)

J-GLOBAL ID
200901094395610085
researchmap会員ID
6000001874

肺癌の胸部悪性腫瘍のトランスレーショナル研究、臨床研究を従事している。

論文

 219
  • Ken Akao, Yuko Oya, Takaya Sato, Aki Ikeda, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto, Masashi Kondo, Kazuyoshi Imaizumi
    Exploration of targeted anti-tumor therapy 5(4) 826-840 2024年  
    Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating evidence suggests that ICI chemotherapy is inadequate in this population. Biomarkers of ICI therapy, such as programmed cell death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs), are not biomarkers in patients with EGFR mutations, and the specificity of the tumor microenvironment has been suggested as the reason for this. Combination therapy with PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors is a concern because of its severe toxicity and limited efficacy. However, early-stage NSCLC may differ from advanced-stage NSCLC. In this review, we comprehensively review the current evidence and summarize the potential of ICI therapy in patients with EGFR mutations after acquiring resistance to treatment with EGFR-tyrosine kinase inhibitors (TKIs) with no T790M mutation or whose disease has progressed on osimertinib.
  • 田中 佑典, 石井 友里加, 伊奈 拓摩, 丹羽 義和, 山蔦 久美子, 相馬 智英, 堀口 智也, 後藤 康洋, 磯谷 澄都, 橋本 直純, 近藤 征史, 今泉 和良
    肺癌 63(7) 1021-1021 2023年12月  
  • Takenao Koseki, Mayumi Teramachi, Minako Koga, Minoru S. H. Ko, Tomokazu Amano, Hong Yu, Misa Amano, Erica Leyder, Maria Badiola, Priyanka Ray, Jiyoung Kim, Akihiro C. Ko, Achouak Achour, Nan-ping Weng, Takumi Imai, Hisako Yoshida, Satsuki Taniuchi, Ayumi Shintani, Hidetsugu Fujigaki, Masashi Kondo, Yohei Doi
    Vaccines 11(12) 1767-1767 2023年11月27日  
    mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have played a key role in reducing morbidity and mortality from coronavirus disease 2019 (COVID-19). We conducted a double-blind, placebo-controlled phase I/II trial to evaluate the safety, tolerability, and immunogenicity of EXG-5003, a two-dose, controllable self-replicating RNA vaccine against SARS-CoV-2. EXG-5003 encodes the receptor binding domain (RBD) of SARS-CoV-2 and was administered intradermally without lipid nanoparticles (LNPs). The participants were followed for 12 months. Forty healthy participants were enrolled in Cohort 1 (5 µg per dose, n = 16; placebo, n = 4) and Cohort 2 (25 µg per dose, n = 16; placebo, n = 4). No safety concerns were observed with EXG-5003 administration. SARS-CoV-2 RBD antibody titers and neutralizing antibody titers were not elevated in either cohort. Elicitation of antigen-specific cellular immunity was observed in the EXG-5003 recipients in Cohort 2. At the 12-month follow-up, participants who had received an approved mRNA vaccine (BNT162b2 or mRNA-1273) >1 month after receiving the second dose of EXG-5003 showed higher cellular responses compared with equivalently vaccinated participants in the placebo group. The findings suggest a priming effect of EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines.
  • Aya Hanamoto, Takenao Koseki, Ayaka Utsunomiya, Takuma Ishihara, Takao Tobe, Masashi Kondo, Yuko Kijima, Hiroshi Matsuoka, Tomohiro Mizuno, Takahiro Hayashi, Shigeki Yamada
    Journal of Clinical Medicine 12(22) 6997-6997 2023年11月9日  
    Naldemedine is structurally designed to prevent passage across the blood–brain barrier (BBB), resulting in the attenuation of opioid-induced constipation without interfering with the analgesic effects of opioids. However, the influence of brain metastasis (BM), as one indicator of BBB disruption, on the analgesic effects of opioids in patients treated with naldemedine remains unclear. To examine whether the analgesic effects of opioids following naldemedine treatment are lower in patients with BM than in those without BM, we surveyed inpatients with lung and breast cancers treated with naldemedine at Fujita Health University Hospital between April 2017 and March 2022. Changes in the numeric rating scale (NRS) scores, morphine milligram equivalents (MMEs), and the number of rescues were assessed as analgesia-related outcomes during the first 7 days of naldemedine treatment in patients with or without BM, matched by the propensity score. In total, 172 patients were enrolled. After propensity-score matching, 30 patients with BM and 60 patients without BM were included in the analysis. Changes in NRS scores, MMEs, and the number of rescues did not differ between patients with and without BM. In the linear mixed-effects model, the coefficient of interaction between patients with or without BM and the days for each outcome was not statistically significant. BM does not influence the analgesic effect of opioids in patients with lung and breast cancers treated with naldemedine. Naldemedine may be useful for treating BM.
  • 池田 安紀, 大矢 由子, 佐藤 孝哉, 丹羽 義和, 堀口 智也, 岡地 祥太郎, 後藤 康洋, 磯谷 澄都, 橋本 直純, 近藤 征史, 今泉 和良
    日本気胸・嚢胞性肺疾患学会雑誌 23(2) 73-73 2023年8月  

MISC

 312

共同研究・競争的資金等の研究課題

 3

その他

 1